BIOTECH 2012: Panel of CEOs — Lather, Rinse, Repeat
Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stimulating conversation and a new perspective on the industry.
Read more »NeoChord Medical Device: Can It Mitigate Risk During Heart Surgery?
NeoChord Inc., a venture-backed medical device company focused on minimally-invasive mitral valve repair, yesterday announced that its mitral valve repair system will be featured in the scientific program at the upcoming 26th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).
Read more »CEVEC Pharmaceuticals GmbH Raises € 2.8MM in Series C Financing
CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund.
Read more »OneMedRadio: Intellicell BioSciences CEO Talks Stromal Vascular Cells
Intellicell BioSciences (OTC: SVFC) has pioneered a unique method of acquiring stromal vascular fraction cells derived from the blood vessels in the adult adipose tissue. The company’s proprietary protocol can separate adult autologous VFC cells from the adipose tissue without the use of enzymes.
Read more »Release: Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson’s Disease
The following is a news release published October 25 by Amarantus BioSciences discussing positive behavioural efficacy data for MANF, the company’s powerful therapeutic protein with neuron-protective properties. Data from a neurorestoration 6-hydroxydopamine (6-OHDA) rat model Parkinson’s disease shows superiority of MANF over GDNF.
Read more »DARA Biosciences Execs Discuss Oncology Supportive Care, In-License Portfolio, and Drug Pipeline
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
Read more »Dendreon: Anticancer Immunotherapy, Reimbursement, and New Promises
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Read more »Press Release: Crystal Research Associates to Sponsor 6th Annual OneMedForum
Crystal Research Associates, LLC, an independent equity research firm, announced today a partnership with OneMedPlace to broaden services and provide additional visibility to research clients via the integrated OneMedPlace platform.
Read more »OneMedRadio: Healthtech Conference 2012 — What to Watch For
HealthTech Conference 2012, on October 26th in San Francisco, is a single day summit covering the most important issues in this burgeoning sector. OneMedRadio spoke with Anne Degheest, Managing Director and Founder of HealthTech Capital, about conference programming, and the unique investment opportunity in the sector.
Read more »Special Report: Monitoring the Safety of Post-Market Medical Devices
Tatyana Chorny answered a series of questions written by marcus evans before the forthcoming Medical Device Safety Monitoring and Reporting Conference, January 17-18, 2013 in Las Vegas, NV. Tatyana shares her thoughts on timely reporting and regulatory compliance.
Read more »